Tezemlimogene daxadenorepvec

达艾若替基

Report date: 2025/05/23 16:52:40

Base Information

Drug NameTezemlimogene daxadenorepvec
Drug Alias NameDNX-2440DNX-2450MYX-135Delta 24 ACTDelta-24-RGDOX
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionCell death stimulantsTumor necrosis factor ligand superfamily member 4 Gene transference
TargetsTumor necrosis factor ligand superfamily member 4
Therapy Area/IndicationsPeriampullary CarcinomaLiver NeoplasmsStomach Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDnatrix IncUniversity Of NavarraClinica Universidad De Navarra
Active IndicationsN/A
Inactive IndicationsPeriampullary CarcinomaLiver NeoplasmsStomach Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksN/A